Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Pacer Advisors Inc.

Pacer Advisors Inc. raised its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 5.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,214,480 shares of the specialty pharmaceutical company’s stock after purchasing an additional 115,102 shares during the quarter. Pacer Advisors Inc. owned about 3.66% of Jazz Pharmaceuticals worth $272,713,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC boosted its holdings in shares of Jazz Pharmaceuticals by 55.1% in the second quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 97 shares in the last quarter. UMB Bank n.a. boosted its stake in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock valued at $38,000 after purchasing an additional 129 shares in the last quarter. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 41.3% during the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 121 shares in the last quarter. Itau Unibanco Holding S.A. increased its position in shares of Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after purchasing an additional 172 shares during the period. Finally, Venturi Wealth Management LLC raised its stake in shares of Jazz Pharmaceuticals by 577.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after buying an additional 704 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This represents a 0.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the business’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the sale, the executive vice president now directly owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This represents a 10.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,253 shares of company stock valued at $1,001,434. 4.20% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Robert W. Baird boosted their target price on shares of Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Needham & Company LLC restated a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, December 12th. Royal Bank of Canada reiterated an “outperform” rating and set a $179.00 price objective on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. Finally, Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $140.00 to $175.00 in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $177.00.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $122.04 on Monday. The company has a market capitalization of $7.38 billion, a PE ratio of 17.19, a PEG ratio of 0.87 and a beta of 0.56. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The company’s 50 day moving average price is $122.37 and its 200 day moving average price is $115.45. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $134.17.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.